{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T08:04:56Z","timestamp":1776067496650,"version":"3.50.1"},"reference-count":155,"publisher":"Walter de Gruyter GmbH","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,11,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Central endocannabinoid system (eCBS) is a neuromodulatory system that inhibits potentially harmful, excessive synaptic activation. Endocannabinoid receptors are abundant among brain structures pivotal in different mental disorders development (for example, hippocampus, amygdala, medial-prefrontal cortex, hypothalamus). Here, we review eCBS function in etiology of psychosis, emphasizing its role in dealing with environmental pressures such as traumatic life events. Moreover, we explore eCBS as a guard against hypothalamic-pituitary-adrenal axis over-activation, and discuss its possible role in etiology of different psychopathologies. Additionally, we review eCBS function in creating adaptive behavioral patterns, as we explore its involvement in the memory formation process, extinction learning and emotional response. We discuss eCBS in the context of possible biomarkers of trauma, and in preclinical psychiatric conditions, such as at-risk mental states and clinical high risk states for psychosis. Finally, we describe the role of eCBS in the cannabinoid self-medication-theory and extinction learning.<\/jats:p>","DOI":"10.1515\/revneuro-2020-0102","type":"journal-article","created":{"date-parts":[[2021,3,3]],"date-time":"2021-03-03T07:57:24Z","timestamp":1614758244000},"page":"707-722","source":"Crossref","is-referenced-by-count":3,"title":["Endocannabinoid system in trauma and psychosis: distant guardian of mental stability"],"prefix":"10.1515","volume":"32","author":[{"given":"Tomasz","family":"Bielawski","sequence":"first","affiliation":[{"name":"Department of Psychiatry , Wroclaw Medical University , 10 Pasteur Street , 50-367 Wroclaw , Poland"},{"name":"Department of Physiology , School of Medicine, Louisiana State University Health Sciences Center , New Orleans , LA 70112 , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucas","family":"Albrechet-Souza","sequence":"additional","affiliation":[{"name":"Department of Physiology , School of Medicine, Louisiana State University Health Sciences Center , New Orleans , LA 70112 , USA"},{"name":"Alcohol & Drug Center of Excellence, School of Medicine, Louisiana State University Health Sciences Center , New Orleans , LA 70112 , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dorota","family":"Frydecka","sequence":"additional","affiliation":[{"name":"Department of Psychiatry , Wroclaw Medical University , 10 Pasteur Street , 50-367 Wroclaw , Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2021,3,1]]},"reference":[{"key":"2026041307343291262_j_revneuro-2020-0102_ref_001","doi-asserted-by":"crossref","unstructured":"Aas, M., Pizzagalli, D.A., Laskemoen, J.F., Reponen, E.J., Ueland, T., Melle, I., and Andreassen, O.A. (2019). Elevated hair cortisol is associated with childhood maltreatment and cognitive impairment in schizophrenia and in bipolar disorders. Schizophr. Res. 213: 65\u201371, https:\/\/doi.org\/10.1016\/j.schres.2019.01.011.","DOI":"10.1016\/j.schres.2019.01.011"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_002","doi-asserted-by":"crossref","unstructured":"Addington, J., Cornblatt, B.A., Cadenhead, K.S., Cannon, T.D., McGlashan, T.H., Perkins, D.O., and Heinssen, R. (2011). At clinical high risk for psychosis: outcome for nonconverters. Am. J.\u00a0Psychiatry 168: 800\u2013805, https:\/\/doi.org\/10.1176\/appi.ajp.2011.10081191.","DOI":"10.1176\/appi.ajp.2011.10081191"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_003","doi-asserted-by":"crossref","unstructured":"Adriano, F., Caltagirone, C., and Spalletta, G. (2012). Hippocampal volume reduction in first-episode and chronic schizophrenia: a review and meta-analysis. Neuroscientist 18: 180\u2013200, https:\/\/doi.org\/10.1177\/1073858410395147.","DOI":"10.1177\/1073858410395147"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_004","doi-asserted-by":"crossref","unstructured":"Allan, S.M., Hodgekins, J., Beazley, P., and Oduola, S. (2020). Pathways to care in at\u2010risk mental states: a systematic review. Early Interv. Psychiatry, https:\/\/doi.org\/10.1111\/eip.13053.","DOI":"10.1111\/eip.13053"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_005","doi-asserted-by":"crossref","unstructured":"Althwanay, A., AlZamil, N.A., Almukhadhib, O.Y., Alkhunaizi, S., and Althwanay, R. (2020). Risks and protective factors of the prodromal stage of psychosis: a literature review. Cureus 12.","DOI":"10.7759\/cureus.8639"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_006","doi-asserted-by":"crossref","unstructured":"Appiah-Kusi, E., Wilson, R., Colizzi, M., Foglia, E., Klamerus, E., Caldwell, A., and Bhattacharyya, S. (2019). Childhood trauma and being at-risk for psychosis are associated with higher peripheral endocannabinoids. Psychol. Med. 1\u201310.","DOI":"10.1017\/S0033291719001946"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_007","doi-asserted-by":"crossref","unstructured":"Arseneault, L., Cannon, M., Witton, J., and Murray, R.M. (2004). Causal association between cannabis and psychosis: examination of the evidence. Br. J.\u00a0Psychiatry 184: 110\u2013117, https:\/\/doi.org\/10.1192\/bjp.184.2.110.","DOI":"10.1192\/bjp.184.2.110"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_008","doi-asserted-by":"crossref","unstructured":"Augustin, S.M. and Lovinger, D.M. (2018). Functional relevance of endocannabinoid-dependent synaptic plasticity in the central nervous system. ACS Chem. Neurosci. 9: 2146\u20132161, https:\/\/doi.org\/10.1021\/acschemneuro.7b00508.","DOI":"10.1021\/acschemneuro.7b00508"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_009","doi-asserted-by":"crossref","unstructured":"Baumeister, D., Akhtar, R., Ciufolini, S., Pariante, C.M., and Mondelli, V. (2016). Childhood trauma and adulthood inflammation: a meta-analysis of peripheral C-reactive protein, interleukin-6 and tumour necrosis factor-\u03b1. Mol. Psychiatry 21: 642\u2013649, https:\/\/doi.org\/10.1038\/mp.2015.67.","DOI":"10.1038\/mp.2015.67"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_010","doi-asserted-by":"crossref","unstructured":"Beyer, C.E., Dwyer, J.M., Piesla, M.J., Platt, B.J., Shen, R., Rahman, Z., and Bingham, B. (2010). Depression-like phenotype following chronic CB1 receptor antagonism. Neurobiol. Dis. 39: 148\u2013155, https:\/\/doi.org\/10.1016\/j.nbd.2010.03.020.","DOI":"10.1016\/j.nbd.2010.03.020"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_011","doi-asserted-by":"crossref","unstructured":"Bioque, M., Cabrera, B., Garc\u00eda-Bueno, B., Mac-Dowell, K.S., Torrent, C., Saiz, P.A., and Bernardo, M. (2016). Dysregulated peripheral endocannabinoid system signaling is associated with cognitive deficits in first-episode psychosis. J.\u00a0Psychiatr. Res. 75: 14\u201321, https:\/\/doi.org\/10.1016\/j.jpsychires.2016.01.002.","DOI":"10.1016\/j.jpsychires.2016.01.002"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_012","doi-asserted-by":"crossref","unstructured":"Bioque, M., Garc\u00eda-Bueno, B., MacDowell, K.S., Meseguer, A., Saiz, P.A., Parellada, M., and Bernardo, M. (2013). Peripheral endocannabinoid system dysregulation in first-episode psychosis. Neuropsychopharmacology 38: 2568\u20132577, https:\/\/doi.org\/10.1038\/npp.2013.165.","DOI":"10.1038\/npp.2013.165"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_013","doi-asserted-by":"crossref","unstructured":"Bloomfield, M.A., Morgan, C.J., Egerton, A., Kapur, S., Curran, H.V., and Howes, O.D. (2014). Dopaminergic function in cannabis users and its relationship to cannabis-induced psychotic symptoms. Biol. Psychiatry 75: 470\u2013478, https:\/\/doi.org\/10.1016\/j.biopsych.2013.05.027.","DOI":"10.1016\/j.biopsych.2013.05.027"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_014","doi-asserted-by":"crossref","unstructured":"Borgan, F., Laurikainen, H., Veronese, M., Marques, T.R., Haaparanta-Solin, M., Solin, O., and Di Forti, M. (2019). In vivo availability of cannabinoid 1 receptor levels in patients with first-episode psychosis. JAMA Psychiatry 76: 1074\u20131084, https:\/\/doi.org\/10.1001\/jamapsychiatry.2019.1427.","DOI":"10.1001\/jamapsychiatry.2019.1427"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_015","doi-asserted-by":"crossref","unstructured":"Breitborde, N.J., Srihari, V.H., and Woods, S.W. (2009). Review of the operational definition for first\u2010episode psychosis. Early Interv. Psychiatry 3: 259\u2013265, https:\/\/doi.org\/10.1111\/j.1751-7893.2009.00148.x.","DOI":"10.1111\/j.1751-7893.2009.00148.x"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_016","doi-asserted-by":"crossref","unstructured":"Brewin, C.R., Cloitre, M., Hyland, P., Shevlin, M., Maercker, A., Bryant, R.A., and Somasundaram, D. (2017). A review of current evidence regarding the ICD-11 proposals for diagnosing PTSD and complex PTSD. Clin. Psychol. Rev. 58: 1\u201315, https:\/\/doi.org\/10.1016\/j.cpr.2017.09.001.","DOI":"10.1016\/j.cpr.2017.09.001"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_017","doi-asserted-by":"crossref","unstructured":"Cameron, C., Watson, D., and Robinson, J. (2014). Use of a synthetic cannabinoid in a correctional population for posttraumatic stress disorder\u2013related insomnia and nightmares, chronic pain, harm reduction, and other indications: a retrospective evaluation. J.\u00a0Clin. Psychopharmacol. 34: 559,https:\/\/doi.org\/10.1097\/jcp.0000000000000180.","DOI":"10.1097\/JCP.0000000000000180"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_018","doi-asserted-by":"crossref","unstructured":"Carr, V., Halpin, S., Lau, N., O\u2019Brien, S., Beckmann, J., and Lewin, T. (2000). A risk factor screening and assessment protocol for schizophrenia and related psychosis. Aust. N. Z. J.\u00a0Psychiatry 34: 170\u2013180, https:\/\/doi.org\/10.1080\/000486700240.","DOI":"10.1046\/j.1440-1614.2000.00792.x"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_019","doi-asserted-by":"crossref","unstructured":"Ceccarini, J., De Hert, M., Van Winkel, R., Peuskens, J., Bormans, G., Kranaster, L., and Van Laere, K. (2013). Increased ventral striatal CB1 receptor binding is related to negative symptoms in drug-free patients with schizophrenia. Neuroimage 79: 304\u2013312, https:\/\/doi.org\/10.1016\/j.neuroimage.2013.04.052.","DOI":"10.1016\/j.neuroimage.2013.04.052"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_020","doi-asserted-by":"crossref","unstructured":"Cerqueira, J.J., Almeida, O.F., and Sousa, N. (2008). The stressed prefrontal cortex. Left? Right! Brain. Behav. Immun. 22: 630\u2013638, https:\/\/doi.org\/10.1016\/j.bbi.2008.01.005.","DOI":"10.1016\/j.bbi.2008.01.005"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_021","doi-asserted-by":"crossref","unstructured":"Chiang, K.P., Gerber, A.L., Sipe, J.C., and Cravatt, B.F. (2004). Reduced cellular expression and activity of the P129T mutant of human fatty acid amide hydrolase: evidence for a link between defects in the endocannabinoid system and problem drug use. Hum. Mol. Genet. 13: 2113\u20132119, https:\/\/doi.org\/10.1093\/hmg\/ddh216.","DOI":"10.1093\/hmg\/ddh216"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_022","doi-asserted-by":"crossref","unstructured":"Chouk\u00e8r, A., Kaufmann, I., Kreth, S., Hauer, D., Feuerecker, M., Thieme, D., and Schelling, G. (2010). Motion sickness, stress and the endocannabinoid system. PLoS One 5, https:\/\/doi.org\/10.1371\/journal.pone.0010752.","DOI":"10.1371\/journal.pone.0010752"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_023","doi-asserted-by":"crossref","unstructured":"Cota, D. (2007). CB1 receptors: emerging evidence for central and peripheral mechanisms that regulate energy balance, metabolism, and cardiovascular health. Diabetes Metab. Res. Rev. 23: 507\u2013517, https:\/\/doi.org\/10.1002\/dmrr.764.","DOI":"10.1002\/dmrr.764"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_024","doi-asserted-by":"crossref","unstructured":"Cullen, A.E., Zunszain, P.A., Dickson, H., Roberts, R.E., Fisher, H.L., Pariante, C.M., and Laurens, K.R. (2014). Cortisol awakening response and diurnal cortisol among children at elevated risk for schizophrenia: relationship to psychosocial stress and cognition. Psychoneuroendocrinology 46: 1\u201313, https:\/\/doi.org\/10.1016\/j.psyneuen.2014.03.010.","DOI":"10.1016\/j.psyneuen.2014.03.010"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_025","doi-asserted-by":"crossref","unstructured":"Da Silva, G.E. and Takahashi, R.N. (2002). SR 141716A prevents \u0394 9-tetrahydrocannabinol-induced spatial learning deficit in a Morris-type water maze in mice. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 26: 321\u2013325, https:\/\/doi.org\/10.1016\/s0278-5846(01)00275-5.","DOI":"10.1016\/S0278-5846(01)00275-5"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_026","doi-asserted-by":"crossref","unstructured":"De Marchi, N., De Petrocellis, L., Orlando, P., Daniele, F., Fezza, F., and Di Marzo, V. (2003). Endocannabinoid signalling in the blood of patients with schizophrenia. Lipids Health Dis. 2: 5, https:\/\/doi.org\/10.1186\/1476-511x-2-5.","DOI":"10.1186\/1476-511X-2-5"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_027","doi-asserted-by":"crossref","unstructured":"de Melo Rodrigues, L.C., Conti, C.L., and Nakamura-Palacios, E.M. (2011). Clozapine and SCH 23390 prevent the spatial working memory disruption induced by \u0394 9-THC administration into the medial prefrontal cortex. Brain Res. 1382: 230\u2013237, https:\/\/doi.org\/10.1016\/j.brainres.2011.01.069.","DOI":"10.1016\/j.brainres.2011.01.069"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_028","doi-asserted-by":"crossref","unstructured":"Devane, W.A., Dysarz, F.3., Johnson, M.R., Melvin, L.S., and Howlett, A.C. (1988). Determination and characterization of a cannabinoid receptor in rat brain. Mol. Pharmacol. 34: 605\u2013613.","DOI":"10.1016\/S0026-895X(25)09876-1"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_029","doi-asserted-by":"crossref","unstructured":"Devane, W.A., Hanus, L., Breuer, A., Pertwee, R.G., Stevenson, L.A., Griffin, G., and Mechoulam, R. (1992). Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258: 1946\u20131949, https:\/\/doi.org\/10.1126\/science.1470919.","DOI":"10.1126\/science.1470919"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_030","doi-asserted-by":"crossref","unstructured":"Di Marzo, V., and Despr\u00e9s, J.P. (2009). CB1 antagonists for obesity\u2014what lessons have we learned from rimonabant? Nat. Rev. Endocrinol. 5: 633, https:\/\/doi.org\/10.1038\/nrendo.2009.197.","DOI":"10.1038\/nrendo.2009.197"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_031","doi-asserted-by":"crossref","unstructured":"Dlugos, A., Childs, E., Stuhr, K.L., Hillard, C.J., and De Wit, H. (2012). Acute stress increases circulating anandamide and other N-acylethanolamines in healthy humans. Neuropsychopharmacology 37: 2416\u20132427, https:\/\/doi.org\/10.1038\/npp.2012.100.","DOI":"10.1038\/npp.2012.100"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_032","doi-asserted-by":"crossref","unstructured":"Eggan, S.M., Hashimoto, T., and Lewis, D.A. (2008). Reduced cortical cannabinoid1 receptor messenger RNA and protein expression in schizophrenia. Arch. Gen. Psychiatry 65: 772\u2013784, https:\/\/doi.org\/10.1001\/archpsyc.65.7.772.","DOI":"10.1001\/archpsyc.65.7.772"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_033","doi-asserted-by":"crossref","unstructured":"Eggan, S.M., Lazarus, M.S., Stoyak, S.R., Volk, D.W., Glausier, J.R., Huang, Z.J., and Lewis, D.A. (2012). Cortical glutamic acid decarboxylase 67 deficiency results in lower cannabinoid 1 receptor messenger RNA expression: implications for schizophrenia. Biol. Psychiatry 71: 114\u2013119, https:\/\/doi.org\/10.1016\/j.biopsych.2011.09.014.","DOI":"10.1016\/j.biopsych.2011.09.014"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_034","doi-asserted-by":"crossref","unstructured":"Elms, L., Shannon, S., Hughes, S., and Lewis, N. (2019). Cannabidiol in the treatment of post-traumatic stress disorder: a case series. J.\u00a0Altern. Complement. Med. 25: 392\u2013397, https:\/\/doi.org\/10.1089\/acm.2018.0437.","DOI":"10.1089\/acm.2018.0437"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_035","doi-asserted-by":"crossref","unstructured":"Enman, N.M., Arthur, K., Ward, S.J., Perrine, S.A., and Unterwald, E.M. (2015). Anhedonia, reduced cocaine reward, and dopamine dysfunction in a rat model of posttraumatic stress disorder. Biol. Psychiatry 78: 871\u2013879, https:\/\/doi.org\/10.1016\/j.biopsych.2015.04.024.","DOI":"10.1016\/j.biopsych.2015.04.024"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_036","doi-asserted-by":"crossref","unstructured":"Ferrarelli, F., and Mathalon, D. (2020). The prodromal phase: time to broaden the scope beyond transition to psychosis? Schizophr. Res. 216: 5\u20136, https:\/\/doi.org\/10.1016\/j.schres.2019.12.035.","DOI":"10.1016\/j.schres.2019.12.035"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_037","doi-asserted-by":"crossref","unstructured":"Fowler, I.L., Carr, V.J., Carter, N.T., and Lewin, T.J. (1998). Patterns of current and lifetime substance use in schizophrenia. Schizophr. Bull. 24: 443\u2013455, https:\/\/doi.org\/10.1093\/oxfordjournals.schbul.a033339.","DOI":"10.1093\/oxfordjournals.schbul.a033339"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_038","doi-asserted-by":"crossref","unstructured":"Fusar-Poli, P. (2017). The clinical high-risk state for psychosis (CHR-P), version II. Schizophr. Bull. 43: 44\u20137, https:\/\/doi.org\/10.1093\/schbul\/sbw158.","DOI":"10.1093\/schbul\/sbw158"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_039","doi-asserted-by":"crossref","unstructured":"Gaebel, W., and Zielasek, J. (2015). Focus on psychosis. Dialogues Clin. Neurosci. 17: 9.","DOI":"10.31887\/DCNS.2015.17.1\/wgaebel"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_040","doi-asserted-by":"crossref","unstructured":"Ganon-Elazar, E. and Akirav, I. (2009). Cannabinoid receptor activation in the basolateral amygdala blocks the effects of stress on the conditioning and extinction of inhibitory avoidance. J.\u00a0Neurosci. 29: 11078\u201311088, https:\/\/doi.org\/10.1523\/jneurosci.1223-09.2009.","DOI":"10.1523\/JNEUROSCI.1223-09.2009"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_041","doi-asserted-by":"crossref","unstructured":"Gao, W., Walther, A., Wekenborg, M., Penz, M., and Kirschbaum, C. (2020). Determination of endocannabinoids and N-acylethanolamines in human hair with LC-MS\/MS and their relation to symptoms of depression, burnout, and anxiety. Talanta 217: 121006, https:\/\/doi.org\/10.1016\/j.talanta.2020.121006.","DOI":"10.1016\/j.talanta.2020.121006"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_042","doi-asserted-by":"crossref","unstructured":"Gibson, C.L., Nia, A.B., Spriggs, S.A., DeFrancisco, D., Swift, A., Perkel, C., and Kim-Schulze, S. (2020). Cannabinoid use in psychotic patients impacts inflammatory levels and their association with psychosis severity. Psychiatry Res 293: 113380, https:\/\/doi.org\/10.1016\/j.psychres.2020.113380.","DOI":"10.1016\/j.psychres.2020.113380"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_043","doi-asserted-by":"crossref","unstructured":"Gilpin, N.W., Herman, M.A., and Roberto, M. (2015). The central amygdala as an integrative hub for anxiety and alcohol use disorders. Biol. Psychiatry 77: 859\u2013869, https:\/\/doi.org\/10.1016\/j.biopsych.2014.09.008.","DOI":"10.1016\/j.biopsych.2014.09.008"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_044","doi-asserted-by":"crossref","unstructured":"Giuffrida, A., Leweke, F.M., Gerth, C.W., Schreiber, D., Koethe, D., Faulhaber, J., and Piomelli, D. (2004). Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms. Neuropsychopharmacology 29: 2108\u20132114, https:\/\/doi.org\/10.1038\/sj.npp.1300558.","DOI":"10.1038\/sj.npp.1300558"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_045","doi-asserted-by":"crossref","unstructured":"Glass, M. and Felder, C.C. (1997). Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors augments cAMP accumulation in striatal neurons: evidence for a Gs linkage to the CB1 receptor. J.\u00a0Neurosci. 17: 5327\u20135333, https:\/\/doi.org\/10.1523\/jneurosci.17-14-05327.1997.","DOI":"10.1523\/JNEUROSCI.17-14-05327.1997"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_046","doi-asserted-by":"crossref","unstructured":"Haller, J., Matyas, F., Soproni, K., Varga, B., Barsy, B., Nemeth, B., and Hajos, N. (2007). Correlated species differences in the effects of cannabinoid ligands on anxiety and on GABAergic and glutamatergic synaptic transmission. Eur. J.\u00a0Neurosci. 25: 2445\u20132456, https:\/\/doi.org\/10.1111\/j.1460-9568.2007.05476.x.","DOI":"10.1111\/j.1460-9568.2007.05476.x"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_047","doi-asserted-by":"crossref","unstructured":"Herkenham, M., Lynn, A.B., Johnson, M.R., Melvin, L.S., de Costa, B.R., and Rice, K.C. (1991). Characterization and localization of cannabinoid receptors in rat brain: a quantitative in\u00a0vitro autoradiographic study. J.\u00a0Neurosci. 11: 563\u2013583, https:\/\/doi.org\/10.1523\/jneurosci.11-02-00563.1991.","DOI":"10.1523\/JNEUROSCI.11-02-00563.1991"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_048","doi-asserted-by":"crossref","unstructured":"Hill, M.N. and Tasker, J.G. (2012). Endocannabinoid signaling, glucocorticoid-mediated negative feedback, and regulation of the hypothalamic-pituitary-adrenal axis. Neuroscience 204: 5\u201316, https:\/\/doi.org\/10.1016\/j.neuroscience.2011.12.030.","DOI":"10.1016\/j.neuroscience.2011.12.030"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_049","doi-asserted-by":"crossref","unstructured":"Hill, M.N., Bierer, L.M., Makotkine, I., Golier, J.A., Galea, S., McEwen, B.S., and Yehuda, R. (2013). Reductions in circulating endocannabinoid levels in individuals with post-traumatic stress disorder following exposure to the World Trade Center attacks. Psychoneuroendocrinology 38: 2952\u20132961, https:\/\/doi.org\/10.1016\/j.psyneuen.2013.08.004.","DOI":"10.1016\/j.psyneuen.2013.08.004"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_050","doi-asserted-by":"crossref","unstructured":"Hill, M.N., Hillard, C.J., and McEwen, B.S. (2011). Alterations in corticolimbic dendritic morphology and emotional behavior in cannabinoid CB1 receptor\u2013deficient mice parallel the effects of chronic stress. Cereb. Cortex 21: 2056\u20132064, https:\/\/doi.org\/10.1093\/cercor\/bhq280.","DOI":"10.1093\/cercor\/bhq280"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_051","doi-asserted-by":"crossref","unstructured":"Hill, M.N., McLaughlin, R.J., Bingham, B., Shrestha, L., Lee, T.T., Gray, J.M., and Viau, V. (2010). Endogenous cannabinoid signaling is essential for stress adaptation. Proc. Natl. Acad. Sci. U. S. A. 107: 9406\u20139411, https:\/\/doi.org\/10.1073\/pnas.0914661107.","DOI":"10.1073\/pnas.0914661107"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_052","doi-asserted-by":"crossref","unstructured":"Hill, M.N., Miller, G.E., Carrier, E.J., Gorzalka, B.B., and Hillard, C.J. (2009). Circulating endocannabinoids and N-acyl ethanolamines are differentially regulated in major depression and following exposure to social stress. Psychoneuroendocrinology 34: 1257\u20131262, https:\/\/doi.org\/10.1016\/j.psyneuen.2009.03.013.","DOI":"10.1016\/j.psyneuen.2009.03.013"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_053","doi-asserted-by":"crossref","unstructured":"Hillard, C.J. (2000). Biochemistry and pharmacology of the endocannabinoids arachidonylethanolamide and 2-arachidonylglycerol. Prostag. Other Lipid Mediat. 61: 3\u201318, https:\/\/doi.org\/10.1016\/s0090-6980(00)00051-4.","DOI":"10.1016\/S0090-6980(00)00051-4"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_054","doi-asserted-by":"crossref","unstructured":"Hillard, C.J. (2018). Circulating endocannabinoids: from whence do they come and where are they going? Neuropsychopharmacology 43: 155\u2013172, https:\/\/doi.org\/10.1038\/npp.2017.130.","DOI":"10.1038\/npp.2017.130"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_055","doi-asserted-by":"crossref","unstructured":"Hindocha, C., Freeman, T.P., Schafer, G., Gardner, C., Bloomfield, M.A., Bramon, E., and Curran, H.V. (2020). Acute effects of cannabinoids on addiction endophenotypes are moderated by genes encoding the CB1 receptor and FAAH enzyme. Addiction Biol. 25: 12762, https:\/\/doi.org\/10.1111\/adb.12762.","DOI":"10.1111\/adb.12762"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_056","doi-asserted-by":"crossref","unstructured":"Hirvonen, J., Goodwin, R.S., Li, C.T., Terry, G.E., Zoghbi, S.S., Morse, C., and Innis, R.B. (2012). Reversible and regionally selective downregulation of brain cannabinoid CB 1 receptors in chronic daily cannabis smokers. Mol. Psychiatry 17: 642\u2013649, https:\/\/doi.org\/10.1038\/mp.2011.82.","DOI":"10.1038\/mp.2011.82"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_057","doi-asserted-by":"crossref","unstructured":"Holman, E.A., Guijarro, A., Lim, J., and Piomelli, D. (2014). Effects of acute stress on cardiac endocannabinoids, lipogenesis, and inflammation in rats. Psychosom. Med. 76: 20, https:\/\/doi.org\/10.1097\/psy.0000000000000025.","DOI":"10.1097\/PSY.0000000000000025"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_058","doi-asserted-by":"crossref","unstructured":"Jean\u2010Gilles, L., Braitch, M., Latif, M.L., Aram, J., Fahey, A.J., Edwards, L.J., and Showe, L.C. (2015). Effects of pro\u2010inflammatory cytokines on cannabinoid CB 1 and CB 2 receptors in immune cells. Acta Physiol. 214: 63\u201374, https:\/\/doi.org\/10.1111\/apha.12474.","DOI":"10.1111\/apha.12474"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_059","doi-asserted-by":"crossref","unstructured":"Jiang, B., Xiong, Z., Yang, J., Wang, W., Wang, Y., Hu, Z.L., and Chen, J.G. (2012). Antidepressant\u2010like effects of ginsenoside Rg1 are due to activation of the BDNF signalling pathway and neurogenesis in the hippocampus. Br. J.\u00a0Pharmacol. 166: 1872\u20131887, https:\/\/doi.org\/10.1111\/j.1476-5381.2012.01902.x.","DOI":"10.1111\/j.1476-5381.2012.01902.x"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_060","doi-asserted-by":"crossref","unstructured":"Jo\u00ebls, M., Sarabdjitsingh, R.A., and Karst, H. (2012). Unraveling the time domains of corticosteroid hormone influences on brain activity: rapid, slow, and chronic modes. Pharmacol. Rev. 64: 901\u2013938, https:\/\/doi.org\/10.1124\/pr.112.005892.","DOI":"10.1124\/pr.112.005892"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_061","doi-asserted-by":"crossref","unstructured":"Kathuria, S., Gaetani, S., Fegley, D., Vali\u00f1o, F., Duranti, A., Tontini, A., and Giustino, A. (2003). Modulation of anxiety through blockade of anandamide hydrolysis. Nat. Med. 9: 76\u201381, https:\/\/doi.org\/10.1038\/nm803.","DOI":"10.1038\/nm803"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_062","doi-asserted-by":"crossref","unstructured":"Keen, L.II, Pereira, D., and Latimer, W. (2014). Self-reported lifetime marijuana use and interleukin-6 levels in middle-aged African Americans. Drug Alcohol Depend. 140: 156\u2013160, https:\/\/doi.org\/10.1016\/j.drugalcdep.2014.04.011.","DOI":"10.1016\/j.drugalcdep.2014.04.011"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_063","doi-asserted-by":"crossref","unstructured":"Keller, J., Gomez, R., Williams, G., Lembke, A., Lazzeroni, L., Murphy, G.M., and Schatzberg, A.F. (2017). HPA axis in major depression: cortisol, clinical symptomatology and genetic variation predict cognition. Mol. Psychiatry 22: 527\u2013536, https:\/\/doi.org\/10.1038\/mp.2016.120.","DOI":"10.1038\/mp.2016.120"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_064","doi-asserted-by":"crossref","unstructured":"Knipscheer, J., Sleijpen, M., Frank, L., de Graaf, R., Kleber, R., ten Have, M., and D\u00fcckers, M. (2020). Prevalence of potentially traumatic events, other life events and subsequent reactions indicative for posttraumatic stress disorder in The Netherlands: a general population study based on the trauma screening questionnaire. Int. J.\u00a0Environ. Res. Publ. Health 17: 172, https:\/\/doi.org\/10.3390\/ijerph17051725.","DOI":"10.3390\/ijerph17051725"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_065","doi-asserted-by":"crossref","unstructured":"Koethe, D., Giuffrida, A., Schreiber, D., Hellmich, M., Schultze-Lutter, F., Ruhrmann, S., and Leweke, F.M. (2009). Anandamide elevation in cerebrospinal fluid in initial prodromal states of psychosis. Br. J.\u00a0Psychiatry 194: 371\u2013372, https:\/\/doi.org\/10.1192\/bjp.bp.108.053843.","DOI":"10.1192\/bjp.bp.108.053843"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_066","doi-asserted-by":"crossref","unstructured":"Koethe, D., Pahlisch, F., Hellmich, M., Rohleder, C., Mueller, J.K., Meyer-Lindenberg, A., and Leweke, F.M. (2019). Familial abnormalities of endocannabinoid signaling in schizophrenia. World J.\u00a0Psychiatry 20: 117\u2013125, https:\/\/doi.org\/10.1080\/15622975.2018.1449966.","DOI":"10.1080\/15622975.2018.1449966"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_067","doi-asserted-by":"crossref","unstructured":"K\u00fchn, S., Musso, F., Mobascher, A., Warbrick, T., Winterer, G., and Gallinat, J. (2012). Hippocampal subfields predict positive symptoms in schizophrenia: first evidence from brain morphometry. Transl. Psychiatry 2: 127, https:\/\/doi.org\/10.1038\/tp.2012.51.","DOI":"10.1038\/tp.2012.51"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_068","doi-asserted-by":"crossref","unstructured":"Laprairie, R.B., Bagher, A.M., Kelly, M.E.M., and Denovan\u2010Wright, E.M. (2015). Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor. Br. J.\u00a0Pharmacol. 172: 4790\u20134805, https:\/\/doi.org\/10.1111\/bph.13250.","DOI":"10.1111\/bph.13250"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_069","doi-asserted-by":"crossref","unstructured":"Leweke, F.M., Piomelli, D., Pahlisch, F., Muhl, D., Gerth, C.W., Hoyer, C., and Koethe, D. (2012). Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl. Psychiatry 2: e94, https:\/\/doi.org\/10.1038\/tp.2012.15.","DOI":"10.1038\/tp.2012.15"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_070","doi-asserted-by":"crossref","unstructured":"Lin, C.C., Chen, T.Y., Cheng, P.Y., and Liu, Y.P. (2020). Early life social experience affects adulthood fear extinction deficit and associated dopamine profile abnormalities in a rat model of PTSD. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 109914, https:\/\/doi.org\/10.1016\/j.pnpbp.2020.109914.","DOI":"10.1016\/j.pnpbp.2020.109914"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_071","doi-asserted-by":"crossref","unstructured":"Lin, C.C., Tung, C.S., and Liu, Y.P. (2016). Escitalopram reversed the traumatic stress-induced depressed and anxiety-like symptoms but not the deficits of fear memory. Psychopharmacology 233: 1135\u20131146, https:\/\/doi.org\/10.1007\/s00213-015-4194-5.","DOI":"10.1007\/s00213-015-4194-5"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_072","doi-asserted-by":"crossref","unstructured":"Lisboa, S.F., Resstel, L.B., Aguiar, D.C., and Guimar\u00e3es, F.S. (2008). Activation of cannabinoid CB1 receptors in the dorsolateral periaqueductal gray induces anxiolytic effects in rats submitted to the Vogel conflict test. Eur. J.\u00a0Pharmacol. 593: 73\u201378, https:\/\/doi.org\/10.1016\/j.ejphar.2008.07.032.","DOI":"10.1016\/j.ejphar.2008.07.032"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_073","doi-asserted-by":"crossref","unstructured":"Lisboa, S.F., Vila-Verde, C., Rosa, J., Uliana, D.L., Stern, C.A.J., Bertoglio, L.J., and Guimaraes, F.S. (2019). Tempering aversive\/traumatic memories with cannabinoids: a review of evidence from animal and human studies. Psychopharmacology 236: 201\u2013226, https:\/\/doi.org\/10.1007\/s00213-018-5127-x.","DOI":"10.1007\/s00213-018-5127-x"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_074","doi-asserted-by":"crossref","unstructured":"Luchicchi, A., and Pistis, M. (2012). Anandamide and 2-arachidonoylglycerol: pharmacological properties, functional features, and emerging specificities of the two major endocannabinoids. Mol. Neurobiol. 46: 374\u2013392, https:\/\/doi.org\/10.1007\/s12035-012-8299-0.","DOI":"10.1007\/s12035-012-8299-0"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_075","doi-asserted-by":"crossref","unstructured":"Maccarrone, M., Valverde, O., Barbaccia, M.L., Casta\u00f1\u00e9, A., Maldonado, R., Ledent, C., and Finazzi\u2010Agr\u00f2, A. (2002). Age\u2010related changes of anandamide metabolism in CB1 cannabinoid receptor knockout mice: correlation with behaviour. Eur. J.\u00a0Neurosci. 15: 1178\u20131186, https:\/\/doi.org\/10.1046\/j.1460-9568.2002.01957.x.","DOI":"10.1046\/j.1460-9568.2002.01957.x"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_076","doi-asserted-by":"crossref","unstructured":"MacLean, K.I., and Littleton, J.M. (1977). Environmental stress as a factor in the response of rat brain catecholamine metabolism to \u0394 8-tetrahydrocannabinol. Eur. J.\u00a0Pharmacol. 41: 171\u2013182, https:\/\/doi.org\/10.1016\/0014-2999(77)90206-0.","DOI":"10.1016\/0014-2999(77)90206-0"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_077","doi-asserted-by":"crossref","unstructured":"Madsen, H.B., Guerin, A.A., and Kim, J.H. (2017). Investigating the role of dopamine receptor-and parvalbumin-expressing cells in extinction of conditioned fear. Neurobiol. Learn. Mem. 145: 7\u201317, https:\/\/doi.org\/10.1016\/j.nlm.2017.08.009.","DOI":"10.1016\/j.nlm.2017.08.009"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_078","doi-asserted-by":"crossref","unstructured":"Marsicano, G., Wotjak, C.T., Azad, S.C., Bisogno, T., Rammes, G., Cascio, M.G., and Di Marzo, V. (2002). The endogenous cannabinoid system controls extinction of aversive memories. Nature 418: 530\u2013534, https:\/\/doi.org\/10.1038\/nature00839.","DOI":"10.1038\/nature00839"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_079","doi-asserted-by":"crossref","unstructured":"Martin, M., Ledent, C., Parmentier, M., Maldonado, R., and Valverde, O. (2002). Involvement of CB1 cannabinoid receptors in emotional behaviour. Psychopharmacology 159: 379\u2013387, https:\/\/doi.org\/10.1007\/s00213-001-0946-5.","DOI":"10.1007\/s00213-001-0946-5"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_080","doi-asserted-by":"crossref","unstructured":"Mathers, D.C. and Ghodse, A.H. (1992). Cannabis and psychotic illness. Br. J.\u00a0Psychiatry Psychiatry 161: 648\u2013653, https:\/\/doi.org\/10.1192\/bjp.161.5.648.","DOI":"10.1192\/bjp.161.5.648"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_081","doi-asserted-by":"crossref","unstructured":"Matsuda, L.A., Lolait, S.J., Brownstein, M.J., Young, A.C., and Bonner, T.I. (1990). Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346: 561\u2013564, https:\/\/doi.org\/10.1038\/346561a0.","DOI":"10.1038\/346561a0"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_082","doi-asserted-by":"crossref","unstructured":"McFarlane, A.C., Barton, C.A., Yehuda, R., and Wittert, G. (2011). Cortisol response to acute trauma and risk of posttraumatic stress disorder. Psychoneuroendocrinology 36: 720\u2013727, https:\/\/doi.org\/10.1016\/j.psyneuen.2010.10.007.","DOI":"10.1016\/j.psyneuen.2010.10.007"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_083","doi-asserted-by":"crossref","unstructured":"McGuire, P., Robson, P., Cubala, W.J., Vasile, D., Morrison, P.D., Barron, R., and Wright, S. (2018). Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: a multicenter randomized controlled trial. Am. J.\u00a0Psychiatry 175: 225\u2013231, https:\/\/doi.org\/10.1176\/appi.ajp.2017.17030325.","DOI":"10.1176\/appi.ajp.2017.17030325"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_084","doi-asserted-by":"crossref","unstructured":"Mehta, N.D., Stevens, J.S., Li, Z., Gillespie, C.F., Fani, N., Michopoulos, V., and Felger, J.C. (2020). Inflammation, reward circuitry and symptoms of anhedonia and PTSD in trauma-exposed women. Soc. Cognit. Affect Neurosci. 5: 1046\u20131055, https:\/\/doi.org\/10.1093\/scan\/nsz100.","DOI":"10.1093\/scan\/nsz100"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_085","doi-asserted-by":"crossref","unstructured":"Melis, M., Pistis, M., Perra, S., Muntoni, A.L., Pillolla, G., and Gessa, G.L. (2004). Endocannabinoids mediate presynaptic inhibition of glutamatergic transmission in rat ventral tegmental area dopamine neurons through activation of CB1 receptors. J.\u00a0Neurosci. 24: 53\u201362, https:\/\/doi.org\/10.1523\/jneurosci.4503-03.2004.","DOI":"10.1523\/JNEUROSCI.4503-03.2004"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_086","doi-asserted-by":"crossref","unstructured":"Minichino, A., Senior, M., Brondino, N., Zhang, S.H., Godwlewska, B.R., Burnet, P.W., and Lennox, B.R. (2019). Measuring disturbance of the endocannabinoid system in psychosis: a systematic review and meta-analysis. JAMA Psychiatry 76: 914\u2013923, https:\/\/doi.org\/10.1001\/jamapsychiatry.2019.0970.","DOI":"10.1001\/jamapsychiatry.2019.0970"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_087","doi-asserted-by":"crossref","unstructured":"Mishima, K., Egashira, N., Hirosawa, N., Fujii, M., Matsumoto, Y., Iwasaki, K., and Fujiwara, M. (2001). Characteristics of learning and memory impairment induced by\u22bf 9-tetrahydrocannabinol in rats. Jpn. J.\u00a0Pharmacol. 87: 297\u2013308, https:\/\/doi.org\/10.1254\/jjp.87.297.","DOI":"10.1254\/jjp.87.297"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_088","doi-asserted-by":"crossref","unstructured":"Misiak, B., Krefft, M., Bielawski, T., Moustafa, A.A., S\u0105siadek, M.M., and Frydecka, D. (2017). Toward a unified theory of childhood trauma and psychosis: a comprehensive review of epidemiological, clinical, neuropsychological and biological findings. Neurosci. Biobehav. Rev. 75: 393\u2013406, https:\/\/doi.org\/10.1016\/j.neubiorev.2017.02.015.","DOI":"10.1016\/j.neubiorev.2017.02.015"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_089","doi-asserted-by":"crossref","unstructured":"Mizrahi, R. (2016). Social stress and psychosis risk: common neurochemical substrates? Neuropsychopharmacology 41: 666\u2013674, https:\/\/doi.org\/10.1038\/npp.2015.274.","DOI":"10.1038\/npp.2015.274"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_090","doi-asserted-by":"crossref","unstructured":"Mizrahi, R., Kenk, M., Suridjan, I., Boileau, I., George, T.P., McKenzie, K., and Rusjan, P. (2014). Stress-induced dopamine response in subjects at clinical high risk for schizophrenia with and without concurrent cannabis use. Neuropsychopharmacology 39: 1479\u20131489, https:\/\/doi.org\/10.1038\/npp.2013.347.","DOI":"10.1038\/npp.2013.347"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_091","doi-asserted-by":"crossref","unstructured":"Mondelli, V., Pariante, C.M., Navari, S., Aas, M., D\u2019Albenzio, A., Di Forti, M., and Papadopoulos, A.S. (2010). Higher cortisol levels are associated with smaller left hippocampal volume in first-episode psychosis. Schizophr. Res. 119: 75\u201378, https:\/\/doi.org\/10.1016\/j.schres.2009.12.021.","DOI":"10.1016\/j.schres.2009.12.021"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_092","doi-asserted-by":"crossref","unstructured":"Moreira, F.A., and Wotjak, C.T. (2009). Cannabinoids and anxiety. Behavioral neurobiology of anxiety and its treatment. Curr Top. Behav. Neurosci. 429\u2013450, https:\/\/doi.org\/10.1007\/7854_2009_16.","DOI":"10.1007\/7854_2009_16"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_093","doi-asserted-by":"crossref","unstructured":"Murillo-Rodriguez, E., D\u00e9sarnaud, F., and Prosp\u00e9ro-Garc\u00eda, O. (2006). Diurnal variation of arachidonoylethanolamine, palmitoylethanolamide and oleoylethanolamide in the brain of the rat. Life Sci. 79: 30\u201337, https:\/\/doi.org\/10.1016\/j.lfs.2005.12.028.","DOI":"10.1016\/j.lfs.2005.12.028"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_094","doi-asserted-by":"crossref","unstructured":"Myin-Germeys, I., Marcelis, M., Krabbendam, L., Delespaul, P., and van Os, J. (2005). Subtle fluctuations in psychotic phenomena as functional states of abnormal dopamine reactivity in individuals at risk. Biol. Psychiatry 58: 105\u2013110, https:\/\/doi.org\/10.1016\/j.biopsych.2005.02.012.","DOI":"10.1016\/j.biopsych.2005.02.012"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_095","doi-asserted-by":"crossref","unstructured":"Naderi, N., Haghparast, A., Saber-Tehrani, A., Rezaii, N., Alizadeh, A.M., Khani, A., and Motamedi, F. (2008). Interaction between cannabinoid compounds and diazepam on anxiety-like behaviour of mice. Pharmacol. Biochem. Behav. 89: 64\u201375, https:\/\/doi.org\/10.1016\/j.pbb.2007.11.001.","DOI":"10.1016\/j.pbb.2007.11.001"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_096","doi-asserted-by":"crossref","unstructured":"Newell, K.A., Deng, C., and Huang, X.F. (2006). Increased cannabinoid receptor density in the posterior cingulate cortex in schizophrenia. Exp. Brain Res. 172: 556\u2013560, https:\/\/doi.org\/10.1007\/s00221-006-0503-x.","DOI":"10.1007\/s00221-006-0503-x"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_097","doi-asserted-by":"crossref","unstructured":"Niederhoffer, N., Hansen, H.H., Fernandez\u2010Ruiz, J.J., and Szabo, B. (2001). Effects of cannabinoids on adrenaline release from adrenal medullary cells. Br. J.\u00a0Pharmacol. 134: 1319\u20131327, https:\/\/doi.org\/10.1038\/sj.bjp.0704359.","DOI":"10.1038\/sj.bjp.0704359"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_098","doi-asserted-by":"crossref","unstructured":"Nissen, W., Szabo, A., Somogyi, J., Somogyi, P., and Lamsa, K.P. (2010). Cell type-specific long-term plasticity at glutamatergic synapses onto hippocampal interneurons expressing either parvalbumin or CB1 cannabinoid receptor. J.\u00a0Neurosci. 30: 1337\u20131347, https:\/\/doi.org\/10.1523\/jneurosci.3481-09.2010.","DOI":"10.1523\/JNEUROSCI.3481-09.2010"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_099","doi-asserted-by":"crossref","unstructured":"Norman, R.M., and Malla, A.K. (1993). Stressful life events and schizophrenia: I: a review of the research. Br. J.\u00a0Psychiatry 162: 161\u2013166, https:\/\/doi.org\/10.1192\/bjp.162.2.161.","DOI":"10.1192\/bjp.162.2.161"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_100","doi-asserted-by":"crossref","unstructured":"Pagotto, U., Marsicano, G., Fezza, F., Theodoropoulou, M., Grubler, Y., Stalla, J., and Lutz, B. (2001). Normal human pituitary gland and pituitary adenomas express cannabinoid receptor type 1 and synthesize endogenous cannabinoids: first evidence for a direct role of cannabinoids on hormone modulation at the human pituitary level. J.\u00a0Clin. Endocrinol. Metab. 86: 2687\u20132696, https:\/\/doi.org\/10.1210\/jcem.86.6.7565.","DOI":"10.1210\/jc.86.6.2687"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_101","doi-asserted-by":"crossref","unstructured":"Pan, B., Wang, W., Zhong, P., Blankman, J.L., Cravatt, B.F., and Liu, Q.S. (2011). Alterations of endocannabinoid signaling, synaptic plasticity, learning, and memory in monoacylglycerol lipase knock-out mice. J.\u00a0Neurosci. 31: 13420\u201313430, https:\/\/doi.org\/10.1523\/jneurosci.2075-11.2011.","DOI":"10.1523\/JNEUROSCI.2075-11.2011"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_102","doi-asserted-by":"crossref","unstructured":"Parolaro, D., Realini, N., Vigano, D., Guidali, C., and Rubino, T. (2010). The endocannabinoid system and psychiatric disorders. Exp. Neurol. 224: 3\u201314, https:\/\/doi.org\/10.1016\/j.expneurol.2010.03.018.","DOI":"10.1016\/j.expneurol.2010.03.018"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_103","doi-asserted-by":"crossref","unstructured":"Passos, I.C., Vasconcelos-Moreno, M.P., Costa, L.G., Kunz, M., Brietzke, E., Quevedo, J., and Kauer-Sant\u2019Anna, M. (2015). Inflammatory markers in post-traumatic stress disorder: a systematic review, meta-analysis, and meta-regression. Lancet Psychiatry 2: 1002\u20131012, https:\/\/doi.org\/10.1016\/s2215-0366(15)00309-0.","DOI":"10.1016\/S2215-0366(15)00309-0"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_104","doi-asserted-by":"crossref","unstructured":"Pruessner, M., Bechard-Evans, L., Pira, S., Joober, R., Collins, D.L., Pruessner, J.C., and Malla, A.K. (2017). Interplay of hippocampal volume and hypothalamus-pituitary-adrenal axis function as markers of stress vulnerability in men at ultra-high risk for psychosis. Psychol. Med. 47: 471\u2013483, https:\/\/doi.org\/10.1017\/s0033291716002658.","DOI":"10.1017\/S0033291716002658"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_105","doi-asserted-by":"crossref","unstructured":"Pruessner, M., Lepage, M., Collins, D.L., Pruessner, J.C., Joober, R., and Malla, A.K. (2015). Reduced hippocampal volume and hypothalamus\u2013pituitary\u2013adrenal axis function in first episode psychosis: evidence for sex differences. NeuroImage Clin. 7: 195\u2013202, https:\/\/doi.org\/10.1016\/j.nicl.2014.12.001.","DOI":"10.1016\/j.nicl.2014.12.001"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_106","doi-asserted-by":"crossref","unstructured":"Quinn, H.R., Matsumoto, I., Callaghan, P.D., Long, L.E., Arnold, J.C., Gunasekaran, N., and Matsuda-Matsumoto, H. (2008). Adolescent rats find repeated \u0394 9-THC less aversive than adult rats but display greater residual cognitive deficits and changes in hippocampal protein expression following exposure. Neuropsychopharmacology 33: 1113\u20131126, https:\/\/doi.org\/10.1038\/sj.npp.1301475.","DOI":"10.1038\/sj.npp.1301475"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_107","doi-asserted-by":"crossref","unstructured":"Radhakrishnan, R., Wilkinson, S.T., and D\u2019Souza, D.C. (2014). Gone to pot\u2013a review of the association between cannabis and psychosis. Front. Psychiatry 5: 54, https:\/\/doi.org\/10.3389\/fpsyt.2014.00054.","DOI":"10.3389\/fpsyt.2014.00054"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_108","doi-asserted-by":"crossref","unstructured":"Ranganathan, M., Cortes-Briones, J., Radhakrishnan, R., Thurnauer, H., Planeta, B., Skosnik, P., and Surti, T. (2016). Reduced brain cannabinoid receptor availability in schizophrenia. Biol. Psychiatry 79: 997\u20131005, https:\/\/doi.org\/10.1016\/j.biopsych.2015.08.021.","DOI":"10.1016\/j.biopsych.2015.08.021"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_109","doi-asserted-by":"crossref","unstructured":"Raymundi, A.M., da Silva, T.R., Sohn, J.M., Bertoglio, L.J., and Stern, C.A. (2020). Effects of\u2206 9-tetrahydrocannabinol on aversive memories and anxiety: a review from human studies. BMC Psychiatry 20: 1\u201317, https:\/\/doi.org\/10.1186\/s12888-020-02813-8.","DOI":"10.1186\/s12888-020-02813-8"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_110","doi-asserted-by":"crossref","unstructured":"Reggio, P.H. and Traore, H. (2000). Conformational requirements for endocannabinoid interaction with the cannabinoid receptors, the anandamide transporter and fatty acid amidohydrolase. Chem. Phys. Lipids 108: 15\u201335, https:\/\/doi.org\/10.1016\/s0009-3084(00)00185-7.","DOI":"10.1016\/S0009-3084(00)00185-7"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_111","doi-asserted-by":"crossref","unstructured":"Reuter, A.R., Bumb, J.M., Mueller, J.K., Rohleder, C., Pahlisch, F., Hanke, F., and Schwarz, E. (2017). Association of anandamide with altered binocular depth inversion illusion in schizophrenia. World J.\u00a0Psychiatry 18: 483\u2013488, https:\/\/doi.org\/10.1080\/15622975.2016.1246750.","DOI":"10.1080\/15622975.2016.1246750"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_112","doi-asserted-by":"crossref","unstructured":"Richardson, K.A., Hester, A.K., and McLemore, G.L. (2016). Prenatal cannabis exposure-The \u201cfirst hit\u201d to the endocannabinoid system. Neurotoxicol. Teratol. 58: 5\u201314, https:\/\/doi.org\/10.1016\/j.ntt.2016.08.003.","DOI":"10.1016\/j.ntt.2016.08.003"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_113","doi-asserted-by":"crossref","unstructured":"Rivera, P., del Mar Fern\u00e1ndez-Arjona, M., Silva-Pe\u00f1a, D., Blanco, E., Vargas, A., L\u00f3pez-\u00c1valos, M.D., and Su\u00e1rez, J. (2018). Pharmacological blockade of fatty acid amide hydrolase (FAAH) by URB597 improves memory and changes the phenotype of hippocampal microglia despite ethanol exposure. Biochem. Pharmacol. 157: 244\u2013257, https:\/\/doi.org\/10.1016\/j.bcp.2018.08.005.","DOI":"10.1016\/j.bcp.2018.08.005"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_115","doi-asserted-by":"crossref","unstructured":"Roitman, P., Mechoulam, R., Cooper-Kazaz, R., and Shalev, A. (2014). Preliminary, open-label, pilot study of add-on oral \u0394 9-tetrahydrocannabinol in chronic post-traumatic stress disorder. Clin. Drug Invest. 34: 587\u2013591, https:\/\/doi.org\/10.1007\/s40261-014-0212-3.","DOI":"10.1007\/s40261-014-0212-3"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_116","doi-asserted-by":"crossref","unstructured":"Rosen, J.L., Miller, T.J., D\u2019Andrea, J.T., McGlashan, T.H., and Woods, S.W. (2006). Comorbid diagnoses in patients meeting criteria for the schizophrenia prodrome. Schizophr. Res. 85: 124\u2013131, https:\/\/doi.org\/10.1016\/j.schres.2006.03.034.","DOI":"10.1016\/j.schres.2006.03.034"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_117","doi-asserted-by":"crossref","unstructured":"Sapolsky, R.M., Romero, L.M., and Munck, A.U. (2000). How do glucocorticoids influence stress responses? Integrating permissive, suppressive, stimulatory, and preparative actions. Endocr. Rev. 21: 55\u201389, https:\/\/doi.org\/10.1210\/er.21.1.55.","DOI":"10.1210\/edrv.21.1.0389"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_118","doi-asserted-by":"crossref","unstructured":"Sbarski, B. and Akirav, I. (2020). Cannabinoids as therapeutics for PTSD. Pharmacol. Ther. 107551.","DOI":"10.1016\/j.pharmthera.2020.107551"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_119","doi-asserted-by":"crossref","unstructured":"Scheller, A. and Kirchhoff, F. (2016). Endocannabinoids and heterogeneity of glial cells in brain function. Front. Integr. Neurosci. 10: 24, https:\/\/doi.org\/10.3389\/fnint.2016.00024.","DOI":"10.3389\/fnint.2016.00024"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_120","doi-asserted-by":"crossref","unstructured":"Schoenfeld, T.J., Rhee, D., Martin, L., Smith, J.A., Sonti, A.N., Padmanaban, V., and Cameron, H.A. (2019). New neurons restore structural and behavioral abnormalities in a rat model of PTSD. Hippocampus 29: 848\u2013861, https:\/\/doi.org\/10.1002\/hipo.23087.","DOI":"10.1002\/hipo.23087"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_121","doi-asserted-by":"crossref","unstructured":"Seeman, P. (2006). Targeting the dopamine D2 receptor in schizophrenia. Expert Opin. Ther. Targets 10: 515\u2013531, https:\/\/doi.org\/10.1517\/14728222.10.4.515.","DOI":"10.1517\/14728222.10.4.515"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_122","doi-asserted-by":"crossref","unstructured":"Seif, T., Makriyannis, A., Kunos, G., Bonci, A., and Hopf, F.W. (2011). The endocannabinoid 2-arachidonoylglycerol mediates D1 and D2 receptor cooperative enhancement of rat nucleus accumbens core neuron firing. Neuroscience 193: 21\u201333, https:\/\/doi.org\/10.1016\/j.neuroscience.2011.07.055.","DOI":"10.1016\/j.neuroscience.2011.07.055"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_123","doi-asserted-by":"crossref","unstructured":"Shonesy, B.C., Bluett, R.J., Ramikie, T.S., B\u00e1ldi, R., Hermanson, D.J., Kingsley, P.J., and Patel, S. (2014). Genetic disruption of 2-arachidonoylglycerol synthesis reveals a key role for endocannabinoid signaling in anxiety modulation. Cell Rep. 9: 1644\u20131653, https:\/\/doi.org\/10.1016\/j.celrep.2014.11.001.","DOI":"10.1016\/j.celrep.2014.11.001"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_124","unstructured":"Si, P., Liu, S., Tong, D., Cheng, M., Wang, L., and Cheng, X. (2018). Association of polymorphisms of NAPE-PLD and FAAH genes with schizophrenia in Chinese Han population. Zhonghua yi xue yi chuan xue za zhi [Chin. J. Med. Genet.] 35: 215\u2013218, https:\/\/doi.org\/10.3760\/cma.j.issn.1003-9406.2018.02.015."},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_125","doi-asserted-by":"crossref","unstructured":"Sloan, M.E., Grant, C.W., Gowin, J.L., Ramchandani, V.A., and Le Foll, B. (2019). Endocannabinoid signaling in psychiatric disorders: a review of positron emission tomography studies. Acta Pharmacol. Sin. 40: 342\u2013350, https:\/\/doi.org\/10.1038\/s41401-018-0081-z.","DOI":"10.1038\/s41401-018-0081-z"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_126","doi-asserted-by":"crossref","unstructured":"Stalder, T. and Kirschbaum, C. (2012). Analysis of cortisol in hair\u2013state of the art and future directions. Brain Behav. Immun. 26: 1019\u20131029, https:\/\/doi.org\/10.1016\/j.bbi.2012.02.002.","DOI":"10.1016\/j.bbi.2012.02.002"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_127","doi-asserted-by":"crossref","unstructured":"Steiner, M.A. and Wotjak, C.T. (2008). Role of the endocannabinoid system in regulation of the hypothalamic-pituitary-adrenocortical axis. Prog. Brain Res. 170: 397\u2013432, https:\/\/doi.org\/10.1016\/s0079-6123(08)00433-0.","DOI":"10.1016\/S0079-6123(08)00433-0"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_128","doi-asserted-by":"crossref","unstructured":"Stella, N., Schweitzer, P., and Piomelli, D. (1997). A second endogenous cannabinoid that modulates long-term potentiation. Nature 388: 773\u2013778, https:\/\/doi.org\/10.1038\/42015.","DOI":"10.1038\/42015"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_129","doi-asserted-by":"crossref","unstructured":"Steudte-Schmiedgen, S., Stalder, T., Sch\u00f6nfeld, S., Wittchen, H.U., Trautmann, S., Alexander, N., and Kirschbaum, C. (2015). Hair cortisol concentrations and cortisol stress reactivity predict PTSD symptom increase after trauma exposure during military deployment. Psychoneuroendocrinology 59: 123\u2013133, https:\/\/doi.org\/10.1016\/j.psyneuen.2015.05.00.","DOI":"10.1016\/j.psyneuen.2015.05.007"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_130","doi-asserted-by":"crossref","unstructured":"Sugiura, T., Kondo, S., Sukagawa, A., Nakane, S., Shinoda, A., Itoh, K., and Waku, K. (1995). 2-Arachidonoylgylcerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem. Biophys. Res. Commun. 215: 89\u201397, https:\/\/doi.org\/10.1006\/bbrc.1995.2437.","DOI":"10.1006\/bbrc.1995.2437"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_131","doi-asserted-by":"crossref","unstructured":"Szeszko, P.R., Lehrner, A., and Yehuda, R. (2018). Glucocorticoids and hippocampal structure and function in PTSD. Harv. Rev. Psychiatry 26: 142\u2013157, https:\/\/doi.org\/10.1097\/hrp.000000000000018.","DOI":"10.1097\/HRP.0000000000000188"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_132","doi-asserted-by":"crossref","unstructured":"Teicher, M.H., Andersen, S.L., Polcari, A., Anderson, C.M., Navalta, C.P., and Kim, D.M. (2003). The neurobiological consequences of early stress and childhood maltreatment Neurosci. Biobehav. Rev. 27: 33\u201344, https:\/\/doi.org\/10.1016\/s0149-7634(03)00007-1.","DOI":"10.1016\/S0149-7634(03)00007-1"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_133","doi-asserted-by":"crossref","unstructured":"Thornicroft, G. (1990). Cannabis and psychosis. Br. J.\u00a0Psychiatry 157: 25\u201333, https:\/\/doi.org\/10.1192\/bjp.157.1.25.","DOI":"10.1192\/bjp.157.1.25"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_134","doi-asserted-by":"crossref","unstructured":"Torrisi, S.A., Leggio, G.M., Drago, F., and Salomone, S. (2019). Therapeutic challenges of post-traumatic stress disorder: focus on the dopaminergic system. Front. Pharmacol. 10: 404, https:\/\/doi.org\/10.3389\/fphar.2019.00404.","DOI":"10.3389\/fphar.2019.00404"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_135","doi-asserted-by":"crossref","unstructured":"Urig\u00fcen, L., P\u00e9rez-Rial, S., Ledent, C., Palomo, T., and Manzanares, J. (2004). Impaired action of anxiolytic drugs in mice deficient in cannabinoid CB1 receptors. Neuropharmacology 46: 966\u2013973, https:\/\/doi.org\/10.1016\/j.neuropharm.2004.01.003.","DOI":"10.1016\/j.neuropharm.2004.01.003"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_136","doi-asserted-by":"crossref","unstructured":"van Os, J. and Guloksuz, S. (2017). A critique of the \u201cultra\u2010high risk\u201d and \u201ctransition\u201d paradigm. World Psychiatry 16: 200\u2013206, https:\/\/doi.org\/10.1002\/wps.20423.","DOI":"10.1002\/wps.20423"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_137","doi-asserted-by":"crossref","unstructured":"Varvel, S.A., Cravatt, B.F., Engram, A.E., and Lichtman, A.H. (2006). Fatty acid amide hydrolase (\u2013\/\u2013) mice exhibit an increased sensitivity to the disruptive effects of anandamide or oleamide in a working memory water maze task. J.\u00a0Pharmacol. Exp. Ther. 317: 251\u2013257, https:\/\/doi.org\/10.1124\/jpet.105.095059.","DOI":"10.1124\/jpet.105.095059"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_138","doi-asserted-by":"crossref","unstructured":"Varvel, S., Hamm, R., Martin, B., and Lichtman, A. (2001). Differential effects of \u0394 9-THC on spatial reference and working memory in mice. Psychopharmacology 157: 142\u2013150, https:\/\/doi.org\/10.1007\/s002130100780.","DOI":"10.1007\/s002130100780"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_139","doi-asserted-by":"crossref","unstructured":"Velakoulis, D., Pantelis, C., McGorry, P.D., Dudgeon, P., Brewer, W., Cook, M., and Singh, B. (1999). Hippocampal volume in first-episode psychoses and chronic schizophrenia: a high-resolution magnetic resonance imaging study. Arch. Gen. Psychiatry 56: 133\u2013141, https:\/\/doi.org\/10.1001\/archpsyc.56.2.133.","DOI":"10.1001\/archpsyc.56.2.133"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_140","doi-asserted-by":"crossref","unstructured":"Vigano, D., Guidali, C., Petrosino, S., Realini, N., Rubino, T., Di Marzo, V., and Parolaro, D. (2009). Involvement of the endocannabinoid system in phencyclidine-induced cognitive deficits modelling schizophrenia. Int. J.\u00a0Neuropsychopharmacol. 12: 599\u2013614, https:\/\/doi.org\/10.1017\/s1461145708009371.","DOI":"10.1017\/S1461145708009371"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_141","doi-asserted-by":"crossref","unstructured":"Walder, D.J., Walker, E.F., and Lewine, R.J. (2000). Cognitive functioning, cortisol release, and symptom severity in patients with schizophrenia. Biol. Psychiatry 48: 1121\u20131132, https:\/\/doi.org\/10.1016\/s0006-3223(00)01052-0.","DOI":"10.1016\/S0006-3223(00)01052-0"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_142","doi-asserted-by":"crossref","unstructured":"Walker, E.F., Trotman, H.D., Pearce, B.D., Addington, J., Cadenhead, K.S., Cornblatt, B.A., and Tsuang, M.T. (2013). Cortisol levels and risk for psychosis: initial findings from the North American prodrome longitudinal study. Biol. Psychiatry 74: 410\u2013417, https:\/\/doi.org\/10.1016\/j.biopsych.2013.02.016.","DOI":"10.1016\/j.biopsych.2013.02.016"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_143","doi-asserted-by":"crossref","unstructured":"Wamsteeker, J.I., Kuzmiski, J.B., and Bains, J.S. (2010). Repeated stress impairs endocannabinoid signaling in the paraventricular nucleus of the hypothalamus. J.\u00a0Neurosci. 30: 11188\u201311196, https:\/\/doi.org\/10.1523\/jneurosci.1046-10.2010.","DOI":"10.1523\/JNEUROSCI.1046-10.2010"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_144","doi-asserted-by":"crossref","unstructured":"Watts, J.J., Jacobson, M.R., Lalang, N., Boileau, I., Tyndale, R.F., Kiang, M., and Mizrahi, R. (2020). Imaging brain fatty acid amide hydrolase in untreated patients with psychosis. Biol. Psychiatry.","DOI":"10.1016\/j.biopsych.2020.03.003"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_145","doi-asserted-by":"crossref","unstructured":"Wilker, S., Pfeiffer, A., Elbert, T., Ovuga, E., Karabatsiakis, A., Krumbholz, A., and Kolassa, I.T. (2016). Endocannabinoid concentrations in hair are associated with PTSD symptom severity. Psychoneuroendocrinology 67: 198\u2013206, https:\/\/doi.org\/10.1016\/j.psyneuen.2016.02.010.","DOI":"10.1016\/j.psyneuen.2016.02.010"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_146","doi-asserted-by":"crossref","unstructured":"Wise, L.E., Thorpe, A.J., and Lichtman, A.H. (2009). Hippocampal CB 1 receptors mediate the memory impairing effects of \u0394 9-tetrahydrocannabinol. Neuropsychopharmacology 34: 2072\u20132080, https:\/\/doi.org\/10.1038\/npp.2009.31.","DOI":"10.1038\/npp.2009.31"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_147","doi-asserted-by":"crossref","unstructured":"Wiskerke, J., Irimia, C., Cravatt, B.F., De Vries, T.J., Schoffelmeer, A.N., Pattij, T., and Parsons, L.H. (2012). Characterization of the effects of reuptake and hydrolysis inhibition on interstitial endocannabinoid levels in the brain: an in\u00a0vivo microdialysis study. ACS Chem. Neurosci. 3: 407\u2013417, https:\/\/doi.org\/10.1021\/cn300036b.","DOI":"10.1021\/cn300036b"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_148","doi-asserted-by":"crossref","unstructured":"Wittmann, G., Deli, L., Kall\u00f3, I., Hrabovszky, E., Watanabe, M., Liposits, Z., and Fekete, C. (2007). Distribution of type 1 cannabinoid receptor (CB1)\u2010immunoreactive axons in the mouse hypothalamus. J.\u00a0Comp. Neurol. 503: 270\u2013279, https:\/\/doi.org\/10.1002\/cne.21383.","DOI":"10.1002\/cne.21383"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_149","doi-asserted-by":"crossref","unstructured":"Wolkowitz, O.M., Burke, H., Epel, E.S., and Reus, V.I. (2009). Mood, memory, and mechanisms. Ann. NY Acad. Sci. 1179: 19\u201340, https:\/\/doi.org\/10.1111\/j.1749-6632.2009.04980.x.","DOI":"10.1111\/j.1749-6632.2009.04980.x"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_150","doi-asserted-by":"crossref","unstructured":"Wong, D.F., Kuwabara, H., Horti, A.G., Raymont, V., Brasic, J., Guevara, M., and Rahmim, A. (2010). Quantification of cerebral cannabinoid receptors subtype 1 (CB1) in healthy subjects and schizophrenia by the novel PET radioligand [11C] OMAR. Neuroimage 52: 1505\u20131513, https:\/\/doi.org\/10.1016\/j.neuroimage.2010.04.034.","DOI":"10.1016\/j.neuroimage.2010.04.034"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_151","doi-asserted-by":"crossref","unstructured":"Xu, H., Perez, S., Cornil, A., Detraux, B., Prokin, I., Cui, Y., and Venance, L. (2018). Dopamine\u2013endocannabinoid interactions mediate spike-timing-dependent potentiation in the striatum. Nat. Commun. 9: 1\u201318, https:\/\/doi.org\/10.1038\/s41467-018-06409-5.","DOI":"10.1038\/s41467-018-06409-5"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_152","doi-asserted-by":"crossref","unstructured":"Yung, A.R., Killackey, E., Hetrick, S.E., Parker, A.G., Schultze-Lutter, F., Klosterkoetter, J., and McGorry, P.D. (2007). The prevention of schizophrenia. Int. Rev. Psychiatry 19: 633\u2013646, https:\/\/doi.org\/10.1080\/09540260701797803.","DOI":"10.1080\/09540260701797803"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_153","doi-asserted-by":"crossref","unstructured":"Zanettini, C., Panlilio, L.V., Alicki, M., Goldberg, S.R., Haller, J., and Yasar, S. (2011). Effects of endocannabinoid system modulation on cognitive and emotional behavior. Front. Behav. Neurosci. 5: 57, https:\/\/doi.org\/10.3389\/fnbeh.2011.00057.","DOI":"10.3389\/fnbeh.2011.00057"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_154","doi-asserted-by":"crossref","unstructured":"Zavitsanou, K., Garrick, T., and Huang, X.F. (2004). Selective antagonist [3H] SR141716A binding to cannabinoid CB1 receptors is increased in the anterior cingulate cortex in schizophrenia. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 28: 355\u2013360, https:\/\/doi.org\/10.1016\/j.pnpbp.2003.11.005.","DOI":"10.1016\/j.pnpbp.2003.11.005"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_155","doi-asserted-by":"crossref","unstructured":"Zhuang, J., Yang, D.P., Nikas, S.P., Zhao, J., Guo, J., and Makriyannis, A. (2013). The interaction of fatty acid amide hydrolase (FAAH) inhibitors with an anandamide carrier protein using 19F-NMR. AAPS J. 15: 477\u2013482, https:\/\/doi.org\/10.1208\/s12248-013-9455-9.","DOI":"10.1208\/s12248-013-9455-9"},{"key":"2026041307343291262_j_revneuro-2020-0102_ref_156","doi-asserted-by":"crossref","unstructured":"Ziegler, C.G., Mohn, C., Lamounier-Zepter, V., Rettori, V., Bornstein, S.R., Krug, A.W., and Ehrhart-Bornstein, M. (2010). Expression and function of endocannabinoid receptors in the human adrenal cortex. Horm. Metab. Res. 42: 88\u201392, https:\/\/doi.org\/10.1055\/s-0029-1241860.","DOI":"10.1055\/s-0029-1241860"}],"container-title":["Reviews in the Neurosciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/revneuro-2020-0102\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/revneuro-2020-0102\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T07:37:12Z","timestamp":1776065832000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/revneuro-2020-0102\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,1]]},"references-count":155,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2021,3,1]]},"published-print":{"date-parts":[[2021,11,25]]}},"alternative-id":["10.1515\/revneuro-2020-0102"],"URL":"https:\/\/doi.org\/10.1515\/revneuro-2020-0102","relation":{},"ISSN":["0334-1763","2191-0200"],"issn-type":[{"value":"0334-1763","type":"print"},{"value":"2191-0200","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,1]]}}}